
DGX
USDQuest Diagnostics Incorporated Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$175.820
高値
$176.160
安値
$172.670
出来高
0.13M
企業ファンダメンタルズ
時価総額
19.6B
業種
Diagnostics & Research
国
United States
取引統計
平均出来高
1.36M
取引所
NYQ
通貨
USD
52週レンジ
AI分析レポート
最終更新: 2025年4月22日[DGX: Quest Diagnostics Incorporated Common Stock]: Decoding Recent Signals & Potential Moves
Stock Symbol: DGX Generate Date: 2025-04-22 01:34:58
Alright, let's take a look at Quest Diagnostics (DGX). For anyone not glued to financial news, they're a big player in the diagnostics world – think blood tests, disease screenings, that kind of thing. Recent news and stock movements are giving us some interesting signals. Let's break it down without the Wall Street mumbo jumbo.
Recent News Buzz: Good Vibes Overall
The news lately? Mostly positive for Quest. Think of it like this: several smart folks on Wall Street, analysts at firms like Mizuho, Baird, and Redburn Atlantic, have all come out and said "Hey, Quest looks good." They're not just saying "good," they're using terms like "Outperform" and "Buy," which in analyst-speak is a thumbs-up. And they've even bumped up their price targets – basically saying they think the stock price has room to climb, potentially to around $189-$195. That's a decent jump from where it is now.
What's fueling this optimism? A couple of things. Quest is launching new tests, like one for Alzheimer's using a blood sample and another for HPV self-collection for cervical cancer screening. New tests often mean new revenue streams, so that's generally seen as a good thing. Plus, they're about to drop their first quarter financial results – scheduled for today, actually. Anticipation around earnings reports can often give a stock a little boost, or at least keep things interesting.
So, the general feeling from the news is definitely leaning positive. Analysts are optimistic, and the company is rolling out new products.
Price Check: A Bit of a Dip Lately, But...
Now, let's peek at the stock price itself. Over the last month or so, if you look at the numbers, it's been a bit of a rollercoaster. We saw a climb earlier, hitting highs around $170-$175 in late February and early March. But then, things cooled off a bit. More recently, especially in early April, there was a noticeable dip. It dropped from the high $160s down to the low $160s, even touching the $150s briefly. Currently, it's hovering around $163-$164.
Here's the interesting part: even with this recent dip, AI predictions are suggesting a potential short-term bounce. They're forecasting the price to nudge up a bit today and then see a more noticeable jump in the next couple of days – maybe around 2-3% total increase over the next couple of days.
So, while the recent price action might look a little shaky, the AI is hinting at a possible turnaround soon.
Outlook & Strategy Ideas: Maybe Time to Take a Closer Look?
Putting it all together, what are we looking at? The news is positive, analysts are bullish, and AI is predicting a short-term price bump. Despite a recent price dip, this combination might suggest a potential buying opportunity, or at least a reason to keep Quest Diagnostics on your radar.
Potential Entry Consideration: If you're thinking about getting in, the current price range, around $163-$164, could be an area to watch. It's near the recent low point of this dip, and the AI seems to think things could pick up from here. You might even consider waiting for a slight dip closer to $163, as that level seems to be acting as a bit of a support recently.
Potential Exit/Stop-Loss Consideration: If things go as the analysts and AI predict, a potential profit target could be around $167-$170 initially, and perhaps higher towards the analyst price targets of $189-$195 if the positive momentum continues. For managing risk, setting a stop-loss somewhere below the recent lows, maybe around $160 or even a bit lower like $158, could be a smart move. This would help limit potential losses if the stock price decides to keep falling instead of bouncing back.
Company Context Reminder: Quest is in the diagnostics business. News about new tests, healthcare trends, and earnings reports are usually key drivers for their stock. Keep an eye on how their earnings report today is received by the market – that could be a significant catalyst.
In short: Quest Diagnostics is showing some interesting signals. Positive news and AI predictions are hinting at a potential short-term upward move. While nothing is guaranteed in the stock market, it might be worth doing a bit more digging if you're looking for potential opportunities.
Disclaimer: Please remember, this is just an analysis based on the provided information and is intended for informational purposes only. It is not financial advice. Investing in the stock market involves risk, and you could lose money. Always do your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.
関連ニュース
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $190
Truist Securities analyst David Macdonald maintains Quest Diagnostics with a Hold and raises the price target from $182 to $190.
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $185
Barclays analyst Stephanie Davis maintains Quest Diagnostics with a Equal-Weight and raises the price target from $175 to $185.
Baird Maintains Outperform on Quest Diagnostics, Raises Price Target to $194
Baird analyst Eric Coldwell maintains Quest Diagnostics with a Outperform and raises the price target from $191 to $194.
Quest Diagnostics Revenue Rebound, Strategic Moves Fuel Outlook Confidence
Quest Diagnostics Q1 2025 revenue rose to $2.65 billion with EPS of $2.21, exceeding expectations; full-year guidance for sales and EPS reaffirmed.
Quest Diagnostics Reports First Quarter 2025 Financial Results; Reaffirms Revenue and Adjusted Diluted EPS Guidance for Full Year 2025
Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first...
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $189
Mizuho analyst Ann Hynes maintains Quest Diagnostics with a Outperform and raises the price target from $178 to $189.
Quest Diagnostics Launches New AD-Detect™ Blood Test to Aid in Confirming Alzheimer's Disease
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the...
AI予測Beta
AI推奨
更新日時: 2025年4月27日 13:37
74.1% 信頼度
リスクと取引
エントリーポイント
$173.80
利確
$183.22
損切り
$156.41
主要因子
関連株式
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。